Future of Haemophilia Research in India

Ghosh, Kanjaksha; Shukla, Rinku

doi:10.1007/s12288-017-0872-2

Cited by 6 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D-dimer levels have been recommended as a part of the risk stratification criteria to decide anticoagulation ( 83 ).Treatment with low molecular weight heparin (LMWH) is associated with reduction in levels of d-dimer and fibrin degradation products and also in IL-6 levels suggesting a potential anti-inflammatory effect ( 84 ).…”

Section: Association Of Biomarkers With Clinical Phenotype and Therapmentioning

confidence: 99%

Biomarkers in COVID-19: An Up-To-Date Review

2021

View full text Add to dashboard Cite

The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Timely diagnosis and hospitalization, risk stratification, effective utilization of intensive care services, selection of appropriate therapies, monitoring and timely discharge are essential to save the maximum number of lives. Clinical assessment is indispensable, but laboratory markers, or biomarkers, can provide additional, objective information which can significantly impact these components of patient care. COVID-19 is not a localized respiratory infection but a multisystem disease caused by a diffuse systemic process involving a complex interplay of the immunological, inflammatory and coagulative cascades. The understanding of what the virus does to the body and how the body reacts to it has uncovered a gamut of potential biomarkers. This review discusses the different classes of biomarkers – immunological, inflammatory, coagulation, hematological, cardiac, biochemical and miscellaneous – in terms of their pathophysiological basis followed by the current evidence. Differences between children and adults are highlighted. The role of biomarkers in the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C) is reviewed. The correlation of biomarkers with clinical and radiological features and the viral load, temporal evolution and the effect of treatment remain to be studied in detail. Which biomarker needs to be evaluated when and in whom, and how best this information can contribute to patient care are questions which currently lack convincing answers. With the evidence currently available broad guidelines on the rational use of available biomarkers are presented. Integrating clinical and laboratory data, monitoring trends rather than a single value, correlating with the natural course of the disease and tailoring guidelines to the individual patient and healthcare setting are essential.

show abstract

Section: Association Of Biomarkers With Clinical Phenotype and Therapmentioning

confidence: 99%

Biomarkers in COVID-19: An Up-To-Date Review

2021

View full text Add to dashboard Cite

show abstract

“…Severe acute respiratory distress syndrome accompanied by multiorgan dysfunction syndrome has been recognized as a cause of death in most COVID-19 patients. Coagulopathy has been observed in these patients and is consistently associated with poor prognosis [ 5 ]. The mechanism of infection from SARS-CoV-2 involves angiotensin-converting enzyme 2 (ACE-2) receptors on human cells, including endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

“…PE should be suspected in acute worsening of hypoxemia, drop in blood pressure, tachycardia, increased oxygen requirement, and ventilatory settings disproportionate to the severity of pneumonia on chest imaging. CTPA is the criterion standard for diagnosing PE, and a great number of hospital resources were utilized in shifting the patient to the radiology unit [ 5 ]. In the setting of rapid hemodynamic deterioration on anticoagulant treatment, thrombolytic rescue therapy came into consideration [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Progressive COVID-19-Associated Coagulopathy Despite Treatment with Therapeutic Anticoagulation and Thrombolysis

et al. 2021

View full text Add to dashboard Cite

“…1 These cases are expected to swell near 85,000-1,00,000 when investigative techniques, that is, coagulation laboratories become available across 750 districts in the country. 2 India has the second largest number of patients with haemophilia A. 3 80 per cent of Indians with the serious blood disorder are not diagnosed due to the absence of proper diagnostic facilities in the remote area.…”

Section: Patients Are Registered With Haemophiliamentioning

confidence: 99%

“…1 80% of these live in developing countries. 2 India also experiences a significant burden of the disease.…”

Section: Introductionmentioning

confidence: 99%

Assessing the current knowledge, attitude and behaviour of adolescents and young adults living with haemophilia

Mohan

Radhakrishnan²,

Varadarajan

et al. 2020

Haemophilia

View full text Add to dashboard Cite

Introduction: There is significant incidence of Haemophilia in India, with second largest number of persons with Haemophilia A. 20,778 patients registered with Haemophilia Foundation of India in 2018. Research in India includes diagnostic studies, complications and co-morbidities, prenatal diagnosis, inhibitor development and gene therapy. Limited is known about quality of life of these patients. Since Haemophilia leads to the loss of 'normal lifestyle' in young people resulting in emotional distress and depression, it is important to analyse Knowledge, Attitude and Behaviour of persons with Haemophilia. Aim: The aim of the study is to focus on exploring the status of Haemophilia and knowledge, attitude, behaviour of adolescents and youths with haemophilia with the objectives to study 1) the current medical status of haemophilia amongst target population; 2) the knowledge, attitude and behaviour of patients with haemophilia towards their condition. Methods: Respondents in the age group of 15-30 years, who were registered with the Hemophilia Treatment Centers of Government Hospitals/Hemophilia Societies, were interviewed. Data were collected using a structured questionnaire. The study was conducted in two different states and with respondents of two different age groups. Findings: Most respondents suffered from severe haemophilia and co-morbidities such as anxiety, stress, chronic pain and headache. All of them felt that haemophilia interferes in leading a normal life and perceive a grim future. Conclusion: Young people in India need technical, financial and psychological support to prevent complications related to haemophilia. While most of them take responsibility for their health, more behavioural changes need to be inducted to improve quality of life.

show abstract

Future of Haemophilia Research in India

Cited by 6 publications

References 19 publications

Biomarkers in COVID-19: An Up-To-Date Review

Biomarkers in COVID-19: An Up-To-Date Review

Progressive COVID-19-Associated Coagulopathy Despite Treatment with Therapeutic Anticoagulation and Thrombolysis

Assessing the current knowledge, attitude and behaviour of adolescents and young adults living with haemophilia

Contact Info

Product

Resources

About